Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose intravenous decitabine in older AML patients not eligible for standard induction
DRKS00000069Phase 2Active, not recruiting
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in acute myeloid leukemia (AML), sponsored by Universitätsklinikum Freiburg. Started Feb 2009; status: active, not recruiting.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on DRKS00000069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000069.